Blagoy M.
- Country
- Bulgaria
- Department
- NA
Research Overview
- Noninferiority of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide versus beclometasone dipropionate/formoterol fumarate in asthma
- A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma
- Evaluation of Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease Patients
Data & Insights
Has run more than one trial at 207 of 526 partner sites.
Specializations
Chronic Obstructive Pulmonary Disease
The investigator concentrates on improving lung function and lowering exacerbation frequency in patients with Chronic Obstructive Pulmonary Disease, including studies on novel inhaler propellants and adjunctive triple therapy.
- Lung function optimization
- Exacerbation rate reduction
- Propellant innovation
- Triple therapy augmentation
Efforts align with enhancing long‑term respiratory outcomes.
Asthma and Eosinophilic Asthma
Research activities target severe asthma and the eosinophilic phenotype, evaluating biologic add‑on treatments, symptom control metrics, and optimized inhaled regimens.
- Biologic agents for eosinophilic inflammation
- Control questionnaire improvements
- Add‑on therapy evaluation
- ICS/LABA optimization
Targeted strategies aim at sustained symptom control.
Chronic Primary Immune Thrombocytopenia
The focus includes achieving durable platelet responses and confirming long‑term safety of subcutaneous immunotherapies for patients with Chronic Primary Immune Thrombocytopenia.
- Platelet response durability
- Long‑term safety
- Subcutaneous immunotherapy
- Placebo‑controlled efficacy
Research supports alternative treatment pathways for refractory ITP.
Combination Inhaled Pharmacotherapy
Investigations assess fixed‑dose inhaler combinations that integrate ICS, LABA, and LAMA agents, comparing dual and triple regimens and refining device delivery.
- Fixed‑dose triple combinations
- ICS/LABA/LAMA synergy
- Comparative efficacy of dual vs triple regimens
- Device delivery optimization
Studies contribute to streamlined respiratory drug delivery.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.